Enovis (NYSE:ENOV) Director Angela Lalor Acquires 887 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Angela Lalor purchased 887 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were purchased at an average cost of $28.28 per share, for a total transaction of $25,084.36. Following the completion of the transaction, the director directly owned 32,373 shares of the company’s stock, valued at approximately $915,508.44. This represents a 2.82% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Enovis Stock Performance

Shares of ENOV opened at $27.63 on Friday. The firm has a 50-day moving average of $20.36 and a 200-day moving average of $23.19. Enovis Corporation has a one year low of $16.70 and a one year high of $31.81. The company has a market cap of $1.59 billion, a PE ratio of -3.00 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. Enovis’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS. As a group, equities analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENOV. Bank of America Corp DE acquired a new stake in shares of Enovis during the second quarter worth $11,502,000. Legal & General Group Plc acquired a new position in shares of Enovis in the second quarter valued at about $2,753,000. First National Bank of Omaha acquired a new position in shares of Enovis in the second quarter valued at about $1,250,000. Jupiter Topco LLC acquired a new position in shares of Enovis in the second quarter valued at about $2,346,000. Finally, Man Group plc bought a new position in Enovis during the second quarter worth about $8,711,000. Institutional investors own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ENOV shares. Needham & Company LLC lifted their price target on Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. UBS Group restated a “buy” rating and issued a $44.00 price objective on shares of Enovis in a research note on Monday, October 5th. Canaccord Genuity Group cut their price objective on Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Wells Fargo & Company lifted their target price on Enovis from $33.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Finally, BMO Capital Markets set a $27.00 target price on Enovis in a research note on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.62.

Enovis News Roundup

These are some of the ENOV news items that stood out recently:

• Positive Sentiment: Directors Angela S. Lalor and Sharon L. Wienbar reported purchases on November 10 and 11, totaling 3,531 shares worth about $100,000. The buying may bolster investor confidence, although the transactions are relatively modest and do not guarantee future performance. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis said management will present at the Jefferies Global Healthcare Conference in London on November 17. The announcement provides an opportunity for investors to hear from management but disclosed no new financial guidance or business developments. Conference announcement

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.